BKM120 in Metastatic Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of the study drug, BKM120. The study
drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This
protein is found in normal cells and in cancer cells, but often in many cancer cells this
protein is overactive. Inhibiting the protein may slow the growth of prostate cancer but this
has not been tested yet in men with prostate cancer.